Picard Medical Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy PMI?
Source: PRnewswire
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Picard Medical (NYSE:PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating significant investor concern over potential fraud.
- Fraud Allegations: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, while insiders allegedly used offshore accounts to coordinate share dumping during price inflation, highlighting severe governance and transparency issues within the company.
- Investor Action Encouraged: Affected investors are urged to apply for lead plaintiff status by April 3, 2026, suggesting that the case could have substantial implications for the company's future stock price and investor confidence, while also underscoring the legal system's role in upholding market integrity.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their expertise in restoring investor capital and ensuring corporate accountability, which may attract more investors to join the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Picard Medical (NYSE:PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating significant investor concern over potential fraud.
- Fraud Allegations: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, while insiders allegedly used offshore accounts to coordinate share dumping during price inflation, highlighting severe governance and transparency issues within the company.
- Investor Action Encouraged: Affected investors are urged to apply for lead plaintiff status by April 3, 2026, suggesting that the case could have substantial implications for the company's future stock price and investor confidence, while also underscoring the legal system's role in upholding market integrity.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their expertise in restoring investor capital and ensuring corporate accountability, which may attract more investors to join the lawsuit.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations of making false statements during the class period from January 27 to January 29, 2026, misleading investors about the company's business prospects, with a lead plaintiff deadline set for April 3, 2026.
- Picard Medical Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which misled shareholders, and investors must file for lead plaintiff status by April 3, 2026.
- Plug Power Misrepresentation: Plug Power, Inc. is under scrutiny for overstating the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, leading to misleading expectations about future projects, with a deadline for lead plaintiff applications on April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz encourage investors who suffered losses during these periods to contact them for legal advice to ensure their rights are protected in the class actions.
See More
Faruqi & Faruqi Encourages Investors in Picard Medical to Reach Out
- Legal Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical for securities purchased between September 2, 2025, and October 31, 2025, indicating possible legal risks that could undermine investor confidence in the company.
- Investor Contact Information: Investors who suffered losses during the specified period are encouraged to contact securities litigation partner Josh Wilson directly, with two provided phone numbers, reflecting the firm's commitment to supporting affected investors.
- Class Action Deadline: The firm reminds investors of the April 3, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical, emphasizing the urgency for investors to act promptly.
- Market Impact: This investigation and potential class action could negatively affect Picard Medical's stock price, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.
See More
Picard Medical Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Picard Medical (NYSE: PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating strong investor concern over potential fraud.
- Fraud Allegations Details: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonated financial professionals, while insiders allegedly used offshore accounts for coordinated share dumping, highlighting significant failures in the company's disclosure practices.
- Investor Action Guidance: Affected investors are encouraged to apply to be lead plaintiffs by April 3, 2026, with the law firm operating on a contingency fee basis, suggesting potential recovery opportunities for investors who suffered losses.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a reputable firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and investor rights.
See More
Investigation Launched into Picard Medical for Securities Violations
- Stock Price Crash: Picard Medical's stock plummeted approximately 70% during after-hours trading on October 23, 2025, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- Investigation Context: The investigation initiated by the Law Offices of Frank R. Cruz focuses on potential violations of federal securities laws by Picard, indicating heightened scrutiny from regulators that could impact the company's future financing capabilities.
- Social Media Manipulation: Reports reveal that Picard's stock was targeted by an illicit social media promotion scheme, where impersonators falsely touted the company in online forums and social media, potentially leading to stricter regulatory actions against such practices.
- Investor Rights Protection: The law firm is urging all shareholders who invested in Picard Medical to participate in the investigation, highlighting that the legal risks faced by the company could affect its reputation and market trust, prompting investors to seek legal recourse to recover their losses.
See More
Picard Medical Faces Class Action Over Fraud Allegations
- Lawsuit Reminder: Robbins LLP has alerted shareholders that a class action has been filed on behalf of investors who purchased Picard Medical (NYSE:PMI) securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Fraud Allegations: The complaint alleges that Picard Medical failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonated financial professionals, leading to investor losses.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting a severe loss of market confidence in the company.
- Shareholder Action: Shareholders must file their papers by April 3, 2026, to serve as lead plaintiff in the class action, highlighting the urgency of corporate governance and shareholder rights issues.
See More
Picard Medical Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Picard Medical (NYSE:PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating significant investor concern over potential fraud.
- Fraud Allegations: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, while insiders allegedly used offshore accounts to coordinate share dumping during price inflation, highlighting severe governance and transparency issues within the company.
- Investor Action Encouraged: Affected investors are urged to apply for lead plaintiff status by April 3, 2026, suggesting that the case could have substantial implications for the company's future stock price and investor confidence, while also underscoring the legal system's role in upholding market integrity.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their expertise in restoring investor capital and ensuring corporate accountability, which may attract more investors to join the lawsuit.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations of making false statements during the class period from January 27 to January 29, 2026, misleading investors about the company's business prospects, with a lead plaintiff deadline set for April 3, 2026.
- Picard Medical Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which misled shareholders, and investors must file for lead plaintiff status by April 3, 2026.
- Plug Power Misrepresentation: Plug Power, Inc. is under scrutiny for overstating the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, leading to misleading expectations about future projects, with a deadline for lead plaintiff applications on April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz encourage investors who suffered losses during these periods to contact them for legal advice to ensure their rights are protected in the class actions.
See More
Faruqi & Faruqi Encourages Investors in Picard Medical to Reach Out
- Legal Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical for securities purchased between September 2, 2025, and October 31, 2025, indicating possible legal risks that could undermine investor confidence in the company.
- Investor Contact Information: Investors who suffered losses during the specified period are encouraged to contact securities litigation partner Josh Wilson directly, with two provided phone numbers, reflecting the firm's commitment to supporting affected investors.
- Class Action Deadline: The firm reminds investors of the April 3, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical, emphasizing the urgency for investors to act promptly.
- Market Impact: This investigation and potential class action could negatively affect Picard Medical's stock price, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.
See More
Picard Medical Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Picard Medical (NYSE: PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating strong investor concern over potential fraud.
- Fraud Allegations Details: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonated financial professionals, while insiders allegedly used offshore accounts for coordinated share dumping, highlighting significant failures in the company's disclosure practices.
- Investor Action Guidance: Affected investors are encouraged to apply to be lead plaintiffs by April 3, 2026, with the law firm operating on a contingency fee basis, suggesting potential recovery opportunities for investors who suffered losses.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a reputable firm in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its critical role in upholding market integrity and investor rights.
See More
Investigation Launched into Picard Medical for Securities Violations
- Stock Price Crash: Picard Medical's stock plummeted approximately 70% during after-hours trading on October 23, 2025, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- Investigation Context: The investigation initiated by the Law Offices of Frank R. Cruz focuses on potential violations of federal securities laws by Picard, indicating heightened scrutiny from regulators that could impact the company's future financing capabilities.
- Social Media Manipulation: Reports reveal that Picard's stock was targeted by an illicit social media promotion scheme, where impersonators falsely touted the company in online forums and social media, potentially leading to stricter regulatory actions against such practices.
- Investor Rights Protection: The law firm is urging all shareholders who invested in Picard Medical to participate in the investigation, highlighting that the legal risks faced by the company could affect its reputation and market trust, prompting investors to seek legal recourse to recover their losses.
See More
Picard Medical Faces Class Action Over Fraud Allegations
- Lawsuit Reminder: Robbins LLP has alerted shareholders that a class action has been filed on behalf of investors who purchased Picard Medical (NYSE:PMI) securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Fraud Allegations: The complaint alleges that Picard Medical failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonated financial professionals, leading to investor losses.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting a severe loss of market confidence in the company.
- Shareholder Action: Shareholders must file their papers by April 3, 2026, to serve as lead plaintiff in the class action, highlighting the urgency of corporate governance and shareholder rights issues.
See More
